Baxter Cardiovascular Business To Boost R&D Spending After Spin-Off
This article was originally published in The Gray Sheet
Executive Summary
The soon-to-be independent Baxter Cardiovascular Group's R&D spending is expected to increase by 50% over the current coporate rate of 6%.
You may also be interested in...
Edwards' $45 Mil. Sale Of CRI Marks End Of Post-Baxter Restructuring
Edwards Lifesciences has completed the divestment phase of its ongoing reorganization strategy with the sale of its $120 mil. perfusion services business, Cardiovascular Resources, Inc. (CRI), to Fresenius Medical Care for $45 mil.
Edwards' $45 Mil. Sale Of CRI Marks End Of Post-Baxter Restructuring
Edwards Lifesciences has completed the divestment phase of its ongoing reorganization strategy with the sale of its $120 mil. perfusion services business, Cardiovascular Resources, Inc. (CRI), to Fresenius Medical Care for $45 mil.
Baxter To Sell CVG's Products In Fringe International Markets After Spin-off
Baxter Healthcare will continue to distribute products produced by its Cardiovascular Group spin-off in several countries outside of the U.S., including Argentina, Australia, Greece, Ireland, New Zealand and certain Scandinavian countries, after CVG Controlled, Inc. becomes a separate entity in the first half of 2000.